Recent advances in the development of melanocortin-4 receptor agonists

Bibliography

• ANDERSSON PM, BOMAN A, SEIFERT E, SKOTTNER A, TORBJORN L: Ligands to the melanocortin receptors. Expert Opin. Ther. Patents (2001) 11(101583–1592.
   Web of Science ®Google Scholar
• •This article provides a review of the patent literature around melanocortin ligands up until mid 2001.
   Google Scholar
• MACNEIL DJ, HOWARD AD, GUAN X et al.: The role of melanocortins in body weight regulation: opportunities for the treatment of obesity. Eur. Pharmacol (2002) 440:141–157.
   PubMed Web of Science ®Google Scholar
• •This is an excellent review of melanocortins and weight regulation, which includes recent developments in the field.
   Google Scholar
• ABDEL-MALEK ZA: Melanocortin receptors: their functions and regulation by physiological agonists and antagonists. Cell. Mol Life Sci. (2001) 58(3):434–441.
   PubMed Web of Science ®Google Scholar
• MARKS DL, CONE RD: Central melanocortins and the regulation of weight during acute and chronic disease. Recent Progress M Hormone Res. (2001) 56:359–375.
   PubMedGoogle Scholar
• WIKBERG JES, MUCENIECE R, MANDRIKA I et al.: New aspects on the melanocortins and their receptors. Pharmacol Res. (2000) 42(5):393–420.
   PubMed Web of Science ®Google Scholar
• VARIOUS AUTHORS: In: The Melanocortin Receptors. Cone RD (Ed), Humana Press, New Jersey, USA (2000).
   Google Scholar
• •This book provides a comprehensive review of melanocortins.
   Google Scholar
• WIKBERG JES: Melanocortin receptors: new opportunities in drug discovery. Expert Opin. Ther. Patents (2001) 11(1):61–76.
   Web of Science ®Google Scholar
• LU D, WILLARD D, PATEL IR et al.: Agouti protein is an antagonist of the melanocyte-stimulating hormone receptors. Nature (1994) 371:799–802.
   PubMed Web of Science ®Google Scholar
• SHUTTER J, GRAHAM M, KINSEY A et al.: Hypothalamic expression of ART, a novel gene related to agouti, is upregulated in obese and diabetic mutant mice. Genes Dev. (1997) 11:593–602.
   PubMed Web of Science ®Google Scholar
• HUSZAR RRC, LYNCH C, FAIR-HUNTRESS V et al.: Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell (1997) 88:131–141.
   PubMed Web of Science ®Google Scholar
• VERGONI AV, BERTOLINI A, MUTULIS F, WIKBERG JES, SCHIOTH HB: Differential influence of a selective melanocortin MC4 receptor antagonist (H5014) on melanocortin-induced behavioural effects in rats. Eur. Pharmacol (1998) 362:95–101.
   PubMed Web of Science ®Google Scholar
• KASK A, PAHKLA R, IRS A et al.: Long-term administration of MC4 receptor antagonist H5014 causes hyperphagia and obesity in rats. NeuroReport (1999) 10:707–711.
   PubMed Web of Science ®Google Scholar
• HAMILTON BS, DOODS HN: Chronic application of MTII in a rat model of obesity results in sustained weight loss. Obes. Res. (2002) 10(3):182–187.
   PubMedGoogle Scholar
• DE WIED D, JOLLES J. Neuropeptides derived from proopiocortin: behavioural, physiological, and neurochemical effects. Physiol Rev (1982) 62:976–1059.
   PubMed Web of Science ®Google Scholar
• WESSELLS H, LEVINE N, HADLEY ME, DORR R, HRUBY V: Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int. .1. Impotence Res. (2000) 12\(Suppl. 4):574–579.
   Google Scholar
• VAN DER PLOEG LHT, MARTIN WJ, HOWARD AD et al.: A role for the melanocortin 4 receptor in sexual function. PNAS (2002) 99(17):11381–11386.
   Google Scholar
• •Merck's data with regard to effects of a potent and selective MC4R agonist on erectile function in a rodent model.
   Google Scholar
• YANG Y, FONG TM, DICKINSON CJ et al.: Molecular determinants of ligand binding to the human melanocortin-4 receptor. Biochemistry (2000) 39(48):14900–14911.
   PubMed Web of Science ®Google Scholar
• CHAKI S, NAKAZATO A: Recent advances in feeding suppressing agents: potential therapeutic strategy for the treatment of obesity. Expert Opin. Ther. Patents (2001) 11(11):1677–1692.
   Web of Science ®Google Scholar
• SHADIAK AM: Novel agonists at melanocortin receptors decrease feeding and body weight in rats. SRI Metabolic Diseases Drug Discovery & Development Summit, Philadelphia, USA (2002).
   Google Scholar
• MOLINOFF P, EARLE DC, SHADIACK AM: A double-blind placebo-controlled study to evaluate the safety, pharmacokinetics, and erectogenic effect of subcutaneously administered PT-141 in healthy males. American Urological Association Annual Meeting. Orlando, USA (2002) LB38.
   Google Scholar
• •Clinical data is provided on a melanocortin agonist for sexual dysfunction.
   Google Scholar
• BEDNAREK MA, MACNEIL T, TANG R, KALYANI RN, VAN DER PLOEG LHT, WEINBERG DH: Potent and selective peptide agonists of a-melanotropin action at human melanocortin receptor 4: their synthesis and biological evaluation in vitro. Biochem. Biophys. Res. Commun. (2001) 286:641–645.
   PubMed Web of Science ®Google Scholar
• KAVARANA MJ, TRIVEDI D, CAI Metal: Novel cyclic templates of a-MSH give highly selective and potent antagonists/agonists for human melanocortin-3/4 receptors. j. Med. Chem. (2002) 45(12):2644–2650.
   PubMed Web of Science ®Google Scholar
• NARGUND RP SEBHAT I, YE Z et al: Design and biological profile for selective agonists for the melanocortin subtype-4 receptor. Abstracts of Papers, 222" ACS National Meeting, Chicago, IL, USA (2001) 639970.
   Google Scholar
• SEBHAT IK: Erectogenic effects of potent,selective, non-peptide melanocortin subtype-4 receptor (MC4R) agonists. Cordon Conference on Medicinal Chemistry Colby Sawyer College (2001).
   Google Scholar
• •Merck's data with regard to effects of a potent and selective MC4R agonist on erectile function in a rodent model.
   Google Scholar
• SKOTTNER A, RAPOSINHO P, AUBERT M et al: Melanocortin 4 receptor agonists and effects on food intake; a multivariate analysis. Keystone Symposium on the Molecular Condo] of Adipogenesis and Obesio,, Keystone, CO, USA (2002) Poster abstract 411.
   Google Scholar
• •A potent MC4R agonist with oral efficacy in a rodent model of obesity.
   Google Scholar
• XIAO L, LUO J, TOZZO L et al.: Oral melanocortin 4 receptor agonists for the treatment of obesity and type 2 diabetes. Keystone Symposium on the Molecular Control of Adipogenesis and Obesity Keystone, CO, USA (2002) Poster abstract 310.
   Google Scholar
• •A potent and selective MC4R agonist with oral efficacy in rodent models of obesity.
   Google Scholar
• PILLAI O, DHANIKULA AB, PANCHAGNULA R: Drug delivery: an odyssey of 100 years. Curt: Opin. Chem. Biol. (2001) 5(4):439–446.
   PubMed Web of Science ®Google Scholar
• LI S: Advances in drug delivery and formulation technologies. Frontiers Biotech. Pharm. (2001) 2:189–201.
   Google Scholar
• YANCOPOULOS GD: CNTF/Axokine causes weight loss via leptin-like pathway in mice and man. SRI Metabolic Diseases Drug Discovery & Development Summit, Philadelphia, USA (2002).
   Google Scholar